Cabergoline Monitoring Guidelines for Hyperprolactinemia and Prolactinomas

Clinical and Biochemical Monitoring

The Endocrine Society recommends measuring serum prolactin levels regularly to assess treatment response, initially every 3-6 months until stabilized, for patients on cabergoline for hyperprolactinemia or prolactinomas 2, 3
Clinical symptoms including growth, puberty, galactorrhoea, menstrual history, gynaecomastia, and libido in adolescents should be monitored, as recommended by the Endocrine Society 4, 5
For patients with normalized prolactin levels for at least 2 years and no visible tumor on MRI, the Endocrine Society suggests considering gradual dose reduction with continued prolactin monitoring for at least 2 more years 4, 5
After cabergoline withdrawal, prolactin levels should be monitored at 3-6 month intervals initially to detect biochemical relapse, as recommended by the Endocrine Society 6

For macroprolactinomas, the Endocrine Society recommends repeating MRI 3-6 months after starting cabergoline treatment 4, 5
The imaging schedule for microprolactinomas depends on clinical and biochemical follow-up, according to the Endocrine Society 4, 5
Imaging is recommended before considering cabergoline withdrawal, as suggested by the Endocrine Society 4, 5
The long-term imaging frequency should be determined by symptoms, biochemical control, and proximity of the tumor to the optic chiasm, as recommended by the Endocrine Society 4, 5

A baseline echocardiogram is recommended before starting cabergoline treatment, as suggested by the American Heart Association and the Endocrine Society 1
Annual echocardiography with cardiac auscultation is recommended for patients receiving >2 mg/week of cabergoline, according to the American Heart Association and the Endocrine Society 1
Echocardiographic surveillance every 5 years is recommended for patients on ≤2 mg/week, as suggested by the American Heart Association and the Endocrine Society 1

The Endocrine Society recommends considering bone mineral density (BMD) assessment 2 years after diagnosis, particularly in adolescent patients 4, 5
BMD results should be interpreted in context of growth, puberty, and clinical status, as suggested by the Endocrine Society 4, 5

For patients resistant to standard doses, the Endocrine Society recommends monitoring response to graduated dose increments up to 3.5 mg/week or up to 7 mg/week in exceptional cases 7
Dopamine agonist resistance is defined as failure to achieve normal prolactin levels and/or less than 50% reduction in tumor area after 3-6 months of maximally tolerated doses, according to the Endocrine Society 2
The Endocrine Society suggests considering surgical intervention if vision deteriorates or does not improve on medical therapy 1

The Endocrine Society recommends monitoring for psychological side effects (mood changes, depression, aggression, hypersexuality, impulse control disorders), which may be more common in children and adolescents 2
Patients with prolactinomas that have invaded sphenoid bone should be watched for cerebrospinal fluid leak (rhinorrhea) after tumor shrinkage, as suggested by the Endocrine Society 2